Epidermal growth factor receptor (EGFR)-tyrosine Kinase inhibitor treatment and salvage chemotherapy in EGFR-mutated elderly pulmonary adenocarcinoma patients

Yen Han Tseng, Yen Chiang Tseng, Yi Hsuan Lin, Yu Chin Lee, Reury Perng Perng, Jacqueline Whang-Peng, Yuh Min Chen

研究成果: 雜誌貢獻文章

4 引文 (Scopus)

摘要

Background. Lung cancer is frequently a disease of elderly patients. However, these patients are often treated less actively owing to a higher comorbidity rate and poor performance status. The efficacy of different treatments in elderly patients with epidermal growth factor receptor (EGFR)-mutated lung cancer is still unknown. Materials and Methods. We retrospectively reviewed the records of our pulmonary adenocarcinoma patients treated between 2010 and 2013. Data on patient age, type of tumor EGFR mutation, response to first-line EGFR-tyrosine kinase inhibitor (TKI) treatment, type of salvage chemotherapy, and efficacy of EGFR-TKI and salvage chemotherapy were collected. Results. In all, 473 of 1,230 stage IV adenocarcinoma patients had an EGFR mutation, and 330 of them received first-line TKI treatment. Of the 330 patients, 160 were $70 years old (elderly group) and 170 were ,70 years old (younger group). The response rate and progression-free survival (PFS) with first-line TKI treatment were not significantly different. The elderly group had shorter median survival. A total of 107 patients received salvage chemotherapy after first-line EGFRTKI treatment: 45 in the elderly group and 62 in the younger group. Their response rate and PFS were not significantly different; however, the younger group had longer median survival. Additional subgroup analysis showed that younger patients who received platinum-based chemotherapy or combination chemotherapy had better median survival than did the elderly patients. The PFS was longer among younger patients receiving a platinum-based regimen than that among the elderly patients. Conclusion. Elderly patients with disease progression after first-line EGFR-TKI treatment can receive chemotherapy and have a response rate similar to that of younger patients.
原文英語
頁(從 - 到)758-766
頁數9
期刊Oncologist
20
發行號7
DOIs
出版狀態已發佈 - 六月 8 2015

指紋

Salvage Therapy
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Drug Therapy
Disease-Free Survival
Adenocarcinoma of lung
Platinum
Survival
Lung Neoplasms
Mutation
Therapeutics
Combination Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

引用此文

Epidermal growth factor receptor (EGFR)-tyrosine Kinase inhibitor treatment and salvage chemotherapy in EGFR-mutated elderly pulmonary adenocarcinoma patients. / Tseng, Yen Han; Tseng, Yen Chiang; Lin, Yi Hsuan; Lee, Yu Chin; Perng, Reury Perng; Whang-Peng, Jacqueline; Chen, Yuh Min.

於: Oncologist, 卷 20, 編號 7, 08.06.2015, p. 758-766.

研究成果: 雜誌貢獻文章

Tseng, Yen Han ; Tseng, Yen Chiang ; Lin, Yi Hsuan ; Lee, Yu Chin ; Perng, Reury Perng ; Whang-Peng, Jacqueline ; Chen, Yuh Min. / Epidermal growth factor receptor (EGFR)-tyrosine Kinase inhibitor treatment and salvage chemotherapy in EGFR-mutated elderly pulmonary adenocarcinoma patients. 於: Oncologist. 2015 ; 卷 20, 編號 7. 頁 758-766.
@article{8ca25ef938564c4e9b48d757498a8365,
title = "Epidermal growth factor receptor (EGFR)-tyrosine Kinase inhibitor treatment and salvage chemotherapy in EGFR-mutated elderly pulmonary adenocarcinoma patients",
abstract = "Background. Lung cancer is frequently a disease of elderly patients. However, these patients are often treated less actively owing to a higher comorbidity rate and poor performance status. The efficacy of different treatments in elderly patients with epidermal growth factor receptor (EGFR)-mutated lung cancer is still unknown. Materials and Methods. We retrospectively reviewed the records of our pulmonary adenocarcinoma patients treated between 2010 and 2013. Data on patient age, type of tumor EGFR mutation, response to first-line EGFR-tyrosine kinase inhibitor (TKI) treatment, type of salvage chemotherapy, and efficacy of EGFR-TKI and salvage chemotherapy were collected. Results. In all, 473 of 1,230 stage IV adenocarcinoma patients had an EGFR mutation, and 330 of them received first-line TKI treatment. Of the 330 patients, 160 were $70 years old (elderly group) and 170 were ,70 years old (younger group). The response rate and progression-free survival (PFS) with first-line TKI treatment were not significantly different. The elderly group had shorter median survival. A total of 107 patients received salvage chemotherapy after first-line EGFRTKI treatment: 45 in the elderly group and 62 in the younger group. Their response rate and PFS were not significantly different; however, the younger group had longer median survival. Additional subgroup analysis showed that younger patients who received platinum-based chemotherapy or combination chemotherapy had better median survival than did the elderly patients. The PFS was longer among younger patients receiving a platinum-based regimen than that among the elderly patients. Conclusion. Elderly patients with disease progression after first-line EGFR-TKI treatment can receive chemotherapy and have a response rate similar to that of younger patients.",
keywords = "Adenocarcinoma, Elderly, Epidermal growth factor receptor, Tyrosine kinase inhibitors",
author = "Tseng, {Yen Han} and Tseng, {Yen Chiang} and Lin, {Yi Hsuan} and Lee, {Yu Chin} and Perng, {Reury Perng} and Jacqueline Whang-Peng and Chen, {Yuh Min}",
year = "2015",
month = "6",
day = "8",
doi = "10.1634/theoncologist.2014-0352",
language = "English",
volume = "20",
pages = "758--766",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "7",

}

TY - JOUR

T1 - Epidermal growth factor receptor (EGFR)-tyrosine Kinase inhibitor treatment and salvage chemotherapy in EGFR-mutated elderly pulmonary adenocarcinoma patients

AU - Tseng, Yen Han

AU - Tseng, Yen Chiang

AU - Lin, Yi Hsuan

AU - Lee, Yu Chin

AU - Perng, Reury Perng

AU - Whang-Peng, Jacqueline

AU - Chen, Yuh Min

PY - 2015/6/8

Y1 - 2015/6/8

N2 - Background. Lung cancer is frequently a disease of elderly patients. However, these patients are often treated less actively owing to a higher comorbidity rate and poor performance status. The efficacy of different treatments in elderly patients with epidermal growth factor receptor (EGFR)-mutated lung cancer is still unknown. Materials and Methods. We retrospectively reviewed the records of our pulmonary adenocarcinoma patients treated between 2010 and 2013. Data on patient age, type of tumor EGFR mutation, response to first-line EGFR-tyrosine kinase inhibitor (TKI) treatment, type of salvage chemotherapy, and efficacy of EGFR-TKI and salvage chemotherapy were collected. Results. In all, 473 of 1,230 stage IV adenocarcinoma patients had an EGFR mutation, and 330 of them received first-line TKI treatment. Of the 330 patients, 160 were $70 years old (elderly group) and 170 were ,70 years old (younger group). The response rate and progression-free survival (PFS) with first-line TKI treatment were not significantly different. The elderly group had shorter median survival. A total of 107 patients received salvage chemotherapy after first-line EGFRTKI treatment: 45 in the elderly group and 62 in the younger group. Their response rate and PFS were not significantly different; however, the younger group had longer median survival. Additional subgroup analysis showed that younger patients who received platinum-based chemotherapy or combination chemotherapy had better median survival than did the elderly patients. The PFS was longer among younger patients receiving a platinum-based regimen than that among the elderly patients. Conclusion. Elderly patients with disease progression after first-line EGFR-TKI treatment can receive chemotherapy and have a response rate similar to that of younger patients.

AB - Background. Lung cancer is frequently a disease of elderly patients. However, these patients are often treated less actively owing to a higher comorbidity rate and poor performance status. The efficacy of different treatments in elderly patients with epidermal growth factor receptor (EGFR)-mutated lung cancer is still unknown. Materials and Methods. We retrospectively reviewed the records of our pulmonary adenocarcinoma patients treated between 2010 and 2013. Data on patient age, type of tumor EGFR mutation, response to first-line EGFR-tyrosine kinase inhibitor (TKI) treatment, type of salvage chemotherapy, and efficacy of EGFR-TKI and salvage chemotherapy were collected. Results. In all, 473 of 1,230 stage IV adenocarcinoma patients had an EGFR mutation, and 330 of them received first-line TKI treatment. Of the 330 patients, 160 were $70 years old (elderly group) and 170 were ,70 years old (younger group). The response rate and progression-free survival (PFS) with first-line TKI treatment were not significantly different. The elderly group had shorter median survival. A total of 107 patients received salvage chemotherapy after first-line EGFRTKI treatment: 45 in the elderly group and 62 in the younger group. Their response rate and PFS were not significantly different; however, the younger group had longer median survival. Additional subgroup analysis showed that younger patients who received platinum-based chemotherapy or combination chemotherapy had better median survival than did the elderly patients. The PFS was longer among younger patients receiving a platinum-based regimen than that among the elderly patients. Conclusion. Elderly patients with disease progression after first-line EGFR-TKI treatment can receive chemotherapy and have a response rate similar to that of younger patients.

KW - Adenocarcinoma

KW - Elderly

KW - Epidermal growth factor receptor

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84936874463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936874463&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2014-0352

DO - 10.1634/theoncologist.2014-0352

M3 - Article

C2 - 26054633

AN - SCOPUS:84936874463

VL - 20

SP - 758

EP - 766

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 7

ER -